Research on genodermatoses using novel genome‐editing tools
Authors:
- 16 June 2017
- journal article
- review article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 15 (8) , 783-789
Abstract
Summary: Genodermatoses comprise a clinically heterogeneous group of mostly devastating disorders affecting the skin. To date, treatment options have in general been limited to symptom relief. However, the recent technical evolution in genome editing has ushered in a new era in the development of causal therapies for rare monogenetic diseases such as genodermatoses. The present review revisits the advantages and drawbacks of engineered nuclease tools currently available: zinc finger nucleases (ZFNs), transcription activator‐like effector nucleases (TALENs), meganucleases, and – the most innovative – clustered regularly interspaced short palindromic repeats (CRISPR)‐associated (Cas) nuclease 9 (CRISPR/Cas9) system. A mechanistic overview of the different modes of action of these programmable nucleases as well as their significance for causal therapy of genodermatoses is presented. Remaining limitations and challenges such as efficient delivery and off‐target activity are critically discussed, highlighting both the past and future of gene therapy in dermatology.Keywords
This publication has 52 references indexed in Scilit:
- RNA‐based therapies for genodermatosesExperimental Dermatology, 2016
- Playing the End Game: DNA Double-Strand Break Repair Pathway ChoiceMolecular Cell, 2012
- RNA-Based Therapeutics: Current Progress and Future ProspectsChemistry & Biology, 2012
- Phenotypic and Genotypic Analyses of Genetic Skin Disease through the Online Mendelian Inheritance in Man (OMIM) DatabaseJournal of Investigative Dermatology, 2009
- Gene Therapy for XSCID: The First Success of Gene TherapyPediatric Research, 2000
- The Ethics of Somatic and Germline Gene TherapyAnnals of the New York Academy of Sciences, 1997
- T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 YearsScience, 1995
- A brief history of gene therapyNature Genetics, 1992
- Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene TransductionNew England Journal of Medicine, 1990
- Gene Therapy for Human Genetic Disease?Science, 1972